Meeting Report
2022–2023 Drug Updates in Hematologic Malignancies
Presented by Rebecca L. Rezac, PharmD, BCOP
From UCHealth Blood Disorders and Cell Therapies Center, Aurora, Colorado
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2024;15(3):177–181 |
https://doi.org/10.6004/jadpro.2024.15.3.4 |
© 2024 BroadcastMed LLC
ABSTRACT
At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring and management of side effects of new therapies for hematologic malignancies.
For access to the full length article, please
sign in.
